

May 5th, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: ESPS Manuscript 17511 Quero .docx).

**Title:** Neoadjuvant or adjuvant therapy for gastric cancer

**Authors:** Laurent Quéro, Sophie Guillerm, Christophe Hennequin

**Name of Journal:** World Journal of Gastrointestinal Oncology

**ESPS Manuscript NO:** 17511

All changes in the text have been highlighted in yellow

The manuscript has been structured and formatted according to the instructions for authors (summary length, author names, institutions and contributions; citations, table 1, abbreviation definitions).

We added a short running title to the manuscript: "gastric cancer treatment"

As requested by the editor, I made an audio file describing our final core tip.

The manuscript has been improved according to the suggestions of reviewers:

**Reviewer #00068348:**

Page 12: In reply to the reviewer #00068348's comment regarding the interaction between neoadjuvant therapies and surgical treatment, we added the following sentence in page 12: "Combining chemotherapy with a targeted therapy may improve the complete pathological response (pCR) and survival, but also individualize therapies and reduce toxicities."

Pages 12 and 13: As recommended by the reviewer #00068348, we have added a new section on targeted therapy and ongoing trials using targeted therapy (HERFLOT, NEOHX...).

We added a new table on ongoing trials using targeted therapy (table 2).

**Reviewer #00503460:**

Pages 12 and 13: As recommended by the reviewer #00503460, we have added a new section on targeted therapy and European ongoing trials using targeted therapy (HERFLOT, NEOHX, INNOVATION).

Table 1: As recommended by the reviewer #00503460, we have added the p values in table 1


**Reviewer #01551804:**

Page 4: We have replaced the word "french" with "French"

Page 11: We have replaced the word "Lapatanib" with "Lapatinib"

Pages 12 and 13: As recommended by the reviewer #01551804, we have added a new section on targeted therapy and ongoing trials using targeted therapy (HERFLOT). In this section, we have also discussed about the possibility of targeted therapy to improve the outcome of advanced resectable gastric cancer.

Sincerely yours,

A handwritten signature in black ink, consisting of several overlapping loops and a long horizontal stroke extending to the right.

Laurent Quéro, MD, PhD  
Radiation Oncology Department  
Saint Louis Hospital  
1 Avenue Claude Vellefaux  
75010 Paris  
Fax: +33-1-4249-4081  
E-mail: [Laurent.quer@sls.aphp.fr](mailto:Laurent.quer@sls.aphp.fr)